Valencia-based SME building AI-powered quantitative imaging biomarker platforms for cancer diagnosis, with deep expertise in radiomics and medical image repositories.
QUIBIM is a Spanish medical imaging AI company that develops quantitative imaging biomarker platforms for clinical use. They build software tools that extract measurable data from MRI and CT scans, turning medical images into structured, quantifiable information for cancer diagnosis and treatment planning. Their core business centers on AI-powered image analysis — particularly for prostate, lung, breast, and colorectal cancers — bridging the gap between radiological imaging and precision medicine. They also provide cloud infrastructure and regulatory-compliant repositories for medical imaging data.
Founded their H2020 participation on this exact capability — QUIBIM, QUIBIM Precision, PRIMAGE, CHAIMELEON, ProCAncer-I, and qp-Prostate all center on extracting quantitative biomarkers from medical images.
PRIMAGE (neuroblastoma/DIPG), CHAIMELEON (lung, breast, colorectal cancer), ProCAncer-I (prostate cancer), and qp-Prostate demonstrate deep focus on AI tools for cancer management across multiple tumor types.
CHAIMELEON and ProCAncer-I both involve building repositories of annotated medical images with cloud infrastructure, while ATMOSPHERE addressed cloud platform security.
PRIMAGE focused on predictive in-silico multiscale analytics and modelling, while CHAIMELEON explicitly addresses radiomics for cancer management.
PainFACT (2020-2025) applies their imaging and biomarker expertise to chronic pain, fatigue, depression, and cardiovascular comorbidities — a significant expansion beyond oncology.
QUIBIM's early H2020 work (2016-2018) combined cloud infrastructure security (ATMOSPHERE) with their foundational imaging biomarker platform development, including paediatric cancer modelling in PRIMAGE. From 2020 onward, their focus sharpened dramatically toward oncology-specific AI tools — particularly prostate cancer imaging — while also expanding into regulatory compliance for medical AI and multi-cancer data repositories. The shift from building their own platform (SME-1/SME-2 instrument projects) to contributing imaging AI expertise to large research consortia signals a maturing company moving from product development to clinical deployment.
QUIBIM is converging on regulatory-compliant AI tools for oncology imaging, positioning itself as the go-to imaging biomarker partner for cancer-focused EU consortia.
QUIBIM operates as both a project leader and a specialist partner. They coordinated 3 of their 8 projects — all SME Instrument grants funding their own product development — while joining 5 larger consortia as a technology contributor. With 63 unique partners across 18 countries, they maintain a broad European network rather than relying on a small circle of repeat collaborators. This pattern suggests a company that is easy to integrate into new consortia and brings a well-defined, modular capability (imaging biomarker analysis) that plugs into diverse research setups.
QUIBIM has collaborated with 63 different partners across 18 countries, indicating wide European reach and strong demand for their imaging biomarker capabilities across diverse consortia. Their network spans clinical research hospitals, AI developers, and cloud infrastructure providers.
QUIBIM occupies a rare niche: a product-focused SME that turns raw medical images into structured, quantitative biomarker data using AI. Unlike academic imaging groups that publish papers, QUIBIM builds deployable software platforms — their SME Instrument trajectory (Phase 1 → Phase 2 → follow-on projects) shows a company scaling from concept to market. For consortium builders, they bring both technical depth in radiomics/imaging AI and commercial urgency around regulatory compliance and clinical adoption.
